Gene therapy plus immunotherapy for advanced head and neck or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment that combines a virus designed to deliver a gene (endostatin) directly into tumors with an immunotherapy drug. It is for people with advanced head and neck cancer or esophageal cancer that has returned or spread after prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older, and for head and neck cancer, under 71; for esophageal cancer, under 76.
- Your cancer must be advanced and confirmed by biopsy: either head and neck cancer or stage IV esophageal squamous cell carcinoma.
- You must have had at least one prior treatment that didn't work or you couldn't tolerate (platinum chemo for head and neck; an immunotherapy for esophageal cancer).
- You must have at least one tumor that the doctor can inject into, either a measurable lesion (head and neck) or a swollen lymph node near the skin (esophageal).
- You must be generally active and able to care for yourself (ECOG score 0-1 or 0-2 depending on cancer type).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a virus-based therapy for locally advanced esophageal squamous cell carcinoma. It aims to see if the virus can target and kill cancer cells while sparing healthy tissue.
This trial tests whether combining immunotherapy with chemotherapy before surgery can help treat adenocarcinoma of the esophagus and stomach junction. It aims to improve outcomes for patients whose cancer can be surgically removed.
This trial tests a new treatment where a specially designed virus carrying an anti-cancer gene is injected directly into tumors in the head and neck area. It's for patients whose cancer has come back or spread after prior chemotherapy and who cannot have surgery or radiation.
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
This trial tests a combination of a new immunotherapy (envafolimab) with standard chemoradiation and a drug that blocks blood vessel growth (endostatin) for people with advanced nasopharyngeal cancer that hasn't been treated before. The goal is to see if this combination works better than the usual treatment.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.